MK
Mythili Koneru
, Chief Medical Officer, Marker Therapeutics · Baylor College of Medicine
Credentials: · ·
History
- Present
Hematology and Medical Oncology
Internal Medicine
Research
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
OncoImmunology · 2015 · First of 5 authors · 383 citations
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Scientific Reports · 2017 · 348 citations
Journal of Translational Medicine · 2015 · First of 5 authors · 238 citations
5 papers
5 papers
- NL
5 papers
4 papers
- DS
3 papers
- DM
3 papers
2 papers
- AJ
2 papers
Clinical trials
- 2023–2027
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Study chair · Recruiting · Phase 1, Phase 2
Remix Therapeutics